国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

以色列Compugen
Compugen 成立于1993年，其宗旨是通過(guò)計算機技術(shù)同生物學(xué)和醫學(xué)的結合，發(fā)現和開(kāi)發(fā)新藥。此公司的優(yōu)勢是具有雄厚的多學(xué)科基礎，其團隊由數學(xué)家、計算機學(xué)家、物理學(xué)家、化學(xué)家和分子生物學(xué)家組成，主要業(yè)務(wù)是用計算機技術(shù)分析和解釋生物學(xué)現象和數據，加速基因組學(xué)、蛋白質(zhì)組學(xué)和其他生物學(xué)數據的處理，研究基因組學(xué)、功能基因組學(xué)和蛋白質(zhì)組學(xué)，研發(fā)針對癌癥、免疫缺陷和神經(jīng)病的生物技術(shù)藥物、藥物靶點(diǎn)和診斷標記。

Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The Company’s increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery – field after field – of numerous therapeutic and diagnostic product candidates. These discovery platforms are based on the Company’s decade-long focus on the predictive understanding of important biological phenomena at the molecular level. Compugen’s current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate – Evogene Ltd. (TASE: EVGN.TA) – to utilize the Company’s in silico predictive discovery capabilities in the agricultural biotechnology field. 

Compugen has been publicly traded on Nasdaq (NASDAQ: CGEN) since August 2000 and on the Tel Aviv Stock Exchange since January 2002.